Search results
Results from the WOW.Com Content Network
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood , and increase HDL .
Evacetrapib: development discontinued in 2015 due to insufficient efficacy. [7] Others: Anacetrapib: In 2017, the REVEAL trial based on more than 30,000 participants showed a modest benefit of the addition of anacetrapib to statin therapy. [8]
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).
The drug had completed several phase III clinical trials, [2] however in May, 2006 AstraZeneca announced that it had discontinued further development. [ 3 ] Cardiac toxicity of tesaglitazar is related to mitochondrial toxicity caused by decrease in PPARγ coactivator 1-α (PPARGC1A, PGC1α) and sirtuin 1 (SIRT1).
1,25 dihydroxycholecalciferol 1-Day 1-deamino-8-d-arginine vasopressin 13-cis-retinoic acid 2'-deoxycoformycin 2-amino-6-mercaptopurine 2-amino-6-trifluoromethoxy-benzothiazole 2-CdA 2-chlorodeoxyadenosine 2-PAM 2-propylpentanoic acid 2-propylvaleric acid 2-pyridine aldoxime methochloride 292 MEP 311C90 3M Avagard (Discontinued) 3M Cavilon Skin ...
Efaproxiral is an analogue of bezafibrate [a lipid-lowering agent], developed for the treatment of depression, traumatic brain injury, ischemia, stroke, myocardial infarction, diabetes, hypoxia, sickle cell disease, hypercholesterolemia and as a radio sensitiser. [1] [2] [3] The chemical is a derivative of propanoic acid.
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ. [1]The drug had completed phase III clinical trials, [2] however in May 2006 Bristol-Myers Squibb announced that it had discontinued further development.